HDAC3:动脉粥样硬化治疗的新靶点OACSTPCD
HDAC3:a new target for atherosclerosis therapy
组蛋白去乙酰化酶3(HDAC3)是一种表观遗传修饰酶,参与动脉粥样硬化(As)的发生发展,寻找有效的HDAC3抑制剂对治疗As具有重要意义.本文综述了HDAC3与As的关系、HDAC3抑制剂最新的研究进展以及一些中药通过抑制HDAC3治疗心血管疾病的作用机制,旨在为研发以HDAC3为靶点的抗As药物提供新的思路.
Histone deacetylase 3(HDAC3)is an epigenetic modification enzyme,which participates in the occur-rence and development of atherosclerosis(As).It is significant to search for effective HDAC3 inhibitors for the treatment of atherosclerosis.This article reviews the relationship between HDAC3 and atherosclerosis,the latest research progress of HDAC3 inhibitors,and the therapeutic effects of some traditional Chinese medicine on cardiovascular diseases by inhibi-ting HDAC3.It aims to provide new ideas for developing anti-atherosclerotic drugs targeting HDAC3.
夏子涵;张和;张紫琼;李星仪;王亦宁;王维蓉
西安交通大学医学部基础医学院实验动物学系,陕西省西安市 710061||西安交通大学医学部转化研究院心血管研究所,陕西省西安市 710061
临床医学
组蛋白去乙酰化酶3动脉粥样硬化抑制剂中药
histone deacetylase 3atherosclerosisinhibitorstraditional Chinese medicine
《中国动脉硬化杂志》 2024 (007)
621-626,640 / 7
国家自然科学基金项目(81873520);陕西省创新能力支撑计划项目(2023-CX-PT-07)
评论